Expanding frontiers, transforming cancer treatment
Your day-by-day guide to ASCO 1 – 5 June 2012 McCormick Place Convention Center Chicago, Illinois, USA Congress site plan
Key presentations
Product key
A Avastin
E Erivedge
H Herceptin
MT MabThera
MM Onartuzumab (MetMAb)
T Tarceva
T Trastuzumab emtansine (T–DM1)
X Xeloda
Z Zelboraf Friday June 1
POSTER DISCUSSION SESSION Gynecologic Cancer
Session time: 13.00 - 17.00 Venue: E450a Presentation time: 16.30 - 17.30 Venue: E354a A Safety of front-line bevacizumab (BEV) combined with weekly paclitaxel (wPAC) and q3w carboplatin (C) for ovarian cancer (OC): results from OCTAVIA. (A. Gonzalez-Martin; Poster Board 6, Abstract # 5017) Saturday June 2
ORAL ABSTRACT SESSIONS Gynecologic Cancer
Session time: 15.00 – 18.00 Venue: E354b Presentation time: 15.00 – 15.15 T Randomised phase III study of erlotinib versus observation in patients with no evidence of disease progression after first line platin-based chemotherapy for ovarian carcinoma. A Gynecological Cancer Intergroup and EORTC-GCG study. (I. Vergote; Abstract # LBA5000)
Session time: 15.00 - 18.00 Venue: E354b Presentation time: 15.30 – 15.45 A AURELIA, a randomized phase III trial evaluating bevacizumab (BEV) combined with chemotherapy (CT) for platinum-resistant recurrent ovarian cancer (OC). (E. Pujade-Lauraine; Abstract # LBA5002)
A Avastin H Herceptin P Pertuzumab
E Erivedge MTP MabThera T Tarceva POSTER DISCUSSION SESSION Head and Neck Cancer
Session time: 08.00 - 12.00 Venue: S102 Presentation time: 12.00 - 13.00 Venue S100a T Expression of p16, ERCC1 and EGFR amplification as predictors of responsiveness of locally advanced squamous cell carcinomas of head and neck (SCCHN) to cisplatin, radiotherapy and erlotinib - a phase II randomized trial. (M.C. Austin; Poster Board 5, Abstract # 5515)
Breast Cancer – HER2/ER
Session time: 13.15 - 17.15 Venue: E450a Presentation time: 16.45 - 17.45 Venue: E Hall D2 Results from a phase 1b study of trastuzumab emtansine P (T-DM1), paclitaxel (T), and pertuzumab (P) in patients with T HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab. (S. Modi; Poster Board 18, Abstract # 528)
Session time: 13.15 - 17.15 Venue: E450a Presentation time: 16.45 - 17.45 Venue: E Hall D2 Cardiac safety in a phase II study of trastuzumab emtansine T (T-DM1) following anthracycline-based chemotherapy as adjuvant or neoadjuvant therapy for early-stage HER2-positive breast cancer. (C.T. Dang; Poster Board 22, Abstract # 532)
MM Onartuzumab (MetMAb) X Xeloda
T Trastuzumab emtansine (T–DM1) Z Zelboraf Saturday June 2
Breast Cancer – HER2/ER
Session time: 13.15 - 17.15 Venue: E450a Presentation time: 16.45 - 17.45 Venue: E Hall D2 H Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast P cancer in the CLEOPATRA study. (M.S. Ewer; Poster Board 23, Abstract # 533)
GENERAL POSTER SESSION Lung Cancer – Non-small Cell Metastatic
Session time: 13.15 – 17.15 Venue: S Hall A2 T Skin toxicity associated with outcome to erlotinib in non-small- cell lung cancer (NSCLC) patients (p) with EGFR mutations in the EURTAC study. (C. Buges; Poster Board 44H, Abstract # 7542)
Session time: 13.15 – 17.15 Venue: S Hall A2 T Differential progression-free survival (PFS) to erlotinib according to EGFR exon 19 deletion type in non-small-cell lung cancer (NSCLC) patients (p) in the EURTAC study. (C.E. Carcereny; Poster Board 44F, Abstract # 7540)
A Avastin H Herceptin P Pertuzumab
E Erivedge MTP MabThera T Tarceva Lung Cancer – Non-small Cell Metastatic
Session time: 13.15 – 17.15 Venue: S Hall A2 T Cutaneous toxicity secondary to erlotinib therapy in patients with non-small cell lung cancer in the NCIC CTG BR.21 study: time course and correlation. (R. Perez-Soler; Poster Board 48G, Abstract # 7573)
Session time: 13.15 – 17.15 Venue: S Hall A2 A AvaALL: open-label randomized phase IIIb trial evaluating the efficacy and safety of standard of care with or without continuous bevacizumab (BV) treatment beyond disease progression in patients (pts) with advanced nonsquamous non-small cell lung cancer (NSCLC) after first-line (1L) treatment with BV plus platinum-doublet chemotherapy (CT). (C. Gridelli; Poster Board 53F, Abstract # TPS7612)
Session time: 13.15 – 17.15 Venue: S Hall A2 T ASPIRATION: Phase II study of continued erlotinib beyond RECIST progression in Asian patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). (K. Park; Poster Board 53H, Abstract # TPS7614)
MM Onartuzumab (MetMAb) X Xeloda
T Trastuzumab emtansine (T–DM1) Z Zelboraf Saturday June 2
Lung Cancer – Non-small Cell Metastatic
Session time: 13.15 – 17.15 Venue: S Hall A2
MM The MetLUNG study: a randomized, double-blind, phase III study of onartuzumab (MetMAb) + erlotinib versus placebo + erlotinib T in patients with advanced, Met-positive non-small cell lung cancer (NSCLC). (D.R. Spigel; Poster Board 54B, Abstract # TPS7616)
A Avastin H Herceptin P Pertuzumab
E Erivedge MTP MabThera T Tarceva Breast Cancer – HER2/ER
Session time: 08.00 – 12.00 Venue: S Hall A2 H Adverse events with pertuzumab and trastuzumab: Evolution during treatment with and without docetaxel in CLEOPATRA. P (J. Baselga; Poster Board 8H, Abstract # 597)
Session time: 08.00 – 12.00 Venue: S Hall A2 H A randomized phase III double-blinded placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu over-expressing metastatic breast cancer (HER2+ MBC): a trial of the Eastern Cooperative Oncology Group (E1105). (C.L. Arteaga; Poster Board 9H, Abstract # 605)
Session time: 13.15 – 17.15 Venue: E450a H Quality of Life Assessment in CLEOPATRA, a Phase III Study Combining Pertuzumab with Trastuzumab and Docetaxel P in Metastatic Breast Cancer. (J. Cortes; Poster Board 9A, Abstract # 598)
Breast Cancer – Triple-Negative/Cytotoxics/Local Therapy
Session time: 08.00 – 12.00 Venue: S Hall A2 Analysis according to prognostic factors in patients (pts) treated A with first-line bevacizumab (BEV) combined with paclitaxel (PAC) for HER2-negative metastatic breast cancer (mBC) in a routine oncology practice study. (I. Schrader; Poster Board 24D, Abstract # 1077)
MM Onartuzumab (MetMAb) X Xeloda
T Trastuzumab emtansine (T–DM1) Z Zelboraf Sunday June 3
PLENARY SESSION Plenary Session Including Science of Oncology Award and Lecture
Session time: 13.00 – 16.00 Venue: N Hall B1 Presentation time: 13.45 – 14.00 T Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) vs capecitabine (X) and lapatinib (L) in X HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane. (K. Blackwell; Abstract # LBA1)
Session time: 13.00 – 16.00 Venue: N Hall B1 Presentation time: 14.45 – 15.00 Bendamustine plus rituximab (B-R) versus CHOP plus MT rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): Updated results from the StiL NHL1 study. (M. Rummel; Abstract # 3)
A Avastin H Herceptin P Pertuzumab
E Erivedge MTP MabThera T Tarceva ORAL ABSTRACT SESSION Gastrointestinal (colorectal cancer)
Session time: 09.45 – 12.45 Venue: E Hall D1 Presentation time: 09.45 – 10.00 T Bevacizumab (Bev) with or without erlotinib as maintenance therapy, following induction first-line chemotherapy plus Bev, in A patients (pts) with metastatic colorectal cancer (mCRC): Efficacy and safety results of the International GERCOR DREAM phase X III trial. (C. Tournigand; Abstract # LBA3500)
Session time: 09.45 – 12.45 Venue: E Hall D1 Presentation time: 10.45 – 11.00 Bevacizumab (BEV) plus chemotherapy (CT) continued A beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV + CT: results of a randomised phase III intergroup study (TML study). (D.E. Arnold, Abstract # CRA3503)
MM Onartuzumab (MetMAb) X Xeloda
T Trastuzumab emtansine (T–DM1) Z Zelboraf Sunday June 3
POSTER DISCUSSION SESSION Lung Cancer - Non-small Cell Local-regional/Small Cell/Other Thoracic Cancers
Session time: 08.00 - 12.00 Venue: E450a Presentation time: 11.30 - 12.30 Venue: E Hall D2 A SWOG S0533: A pilot trial of cisplatin (C)/etoposide (E)/ radiotherapy (RT) followed by consolidation docetaxel (D) and bevacizumab (B) (NSC-704865) in three cohorts of patients (pts) with inoperable locally advanced stage III non-small cell lung cancer (NSCLC). (A.J. Wozniak; Poster Board 10, Abstract # 7018)
Session time: 08.00 - 12.00 Venue: E450a Presentation time: 11.30 - 12.30 Venue: E Hall D2 T The SELECT study: a multicenter phase II trial of adjuvant erlotinib in resected EGFR mutation-positive NSCLC. (J.W. Neal JW; Poster Board 2, Abstract # 7010)
Cancer Prevention/Epidemiology
Session time: 08.00 - 12.00 Venue: S102 H Presentation time: 11.30 - 12.30 Venue: S100a Racial disparities in treatment patterns and clinical outcomes P in patients with HER2-positive metastatic breast cancer. (A.M. T Brufsky; Poster Board 15, Abstract # 1526)
A Avastin H Herceptin P Pertuzumab
E Erivedge MTP MabThera T Tarceva GENERAL POSTER SESSION Melanoma/Skin Cancers
Session time: 08.00 – 12.00 Venue: S Hall A2 E Efficacy and safety of the hedgehog pathway inhibitor vismodegib in patients with advanced basal cell carcinoma (BCC): Erivance BCC study update. (A. Sekulic; Poster Board 36E, Abstract # 8579)
Session time: 08.00 – 12.00 Venue: S Hall A2 Metastatic basal cell carcinoma: Differences in survival by site of E spread. (McCusker M; Poster Board 37C, Abstract # 8585)
Gynecologic Cancer
Session time: 08.00 – 12.00 Venue: S Hall A2 A An updated safety analysis of OCEANS, a randomized, double- blind, phase III trial of gemcitabine (G) and carboplatin (C) with bevacizumab (BV) or placebo (PL) followed by BV or PL to disease progression (PD) in patients with platinum-sensitive (Plat-S) recurrent ovarian cancer. (C. Aghajanian; Poster Board 19F, Abstract # 5054)
MM Onartuzumab (MetMAb) X Xeloda
T Trastuzumab emtansine (T–DM1) Z Zelboraf Monday June 4
ORAL ABSTRACT SESSION Melanoma/Skin Cancers
Session time: 08.00 – 12.00 Venue: E Arie Crown Theater Presentation time: 08.30 – 08.45 Updated overall survival (OS) results for BRIM-3, a phase Z III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbzine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma. (P.B. Chapman; Abstract # 8502)
Session time: 08.00 – 11.00 Venue: E Arie Crown Theater Presentation time: 08.45 – 09.00 Analysis of molecular mechanisms of response and resistance Z to vemurafenib (vem) in BRAFV600E melanoma. (J.A. Sosman; Abstract # 8503)
Head and Neck Cancer
Session time: 08.00 – 11.00 Venue: E354b Presentation time: 09.00 – 09.15 T Randomized phase II trial of cisplatin and radiotherapy with or without erlotinib in patients with localy advanced squamous cell carcinoma of the head and neck. (R. Martins; Abstract # 5503)
A Avastin H Herceptin P Pertuzumab
E Erivedge MTP MabThera T Tarceva Lung Cancer – Non-small Cell Metastatic
Session time: 15.00 – 18.00 Venue: E Hall D2 Presentation time: 15.15 – 15.30 T TAILOR: A phase III trial comparing erlotinib with docetaxel as the second-line treatment of NSCLC patients with wild-type (wt) EGFR. (M. C. Garassino; Abstract # LBA7501)
POSTER DISCUSSION SESSION Breast Cancer – Triple-Negative/Cytotoxics/Local Therapy
Session time: 13.15 - 17.15 Venue: E450b Presentation time: 16.45 - 17.45 Venue: N Hall B1 A Association of a compact 13-gene VEGF-signature is associated with OS in E2100. (S. Willis; Poster Board 19, Abstract # 1027)
MM Onartuzumab (MetMAb) X Xeloda
T Trastuzumab emtansine (T–DM1) Z Zelboraf Monday June 4
GENERAL POSTER SESSION Gastrointestinal (colorectal cancer)
Session time: 08.00 – 12.00 Venue: S Hall A2 A Efficacy and safety of bevacizumab in metastatic colorectal cancer (mCRC): pooled analysis from randomized controlled trials (RCTs). (N.C. Tebbutt; Poster Board 36C, Abstract # 3614)
Session time: 08.00 – 12.00 Venue: S Hall A2 A randomized, phase II, multicenter, double-blind, placebo- MM controlled study evaluating onartuzumab (MetMAb) in A combination with mFOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer. (J.C. Bendell; Poster Board 39E, Abstract # TPS3640)
Session time: 08.00 – 12.00 Venue: S Hall A2 Bevacizumab (BEV) plus capecitabine as maintenance therapy A after initial treatment with BEV plus XELOX in previously X untreated patients (pts) with metastatic colorectal cancer (mCRC): Mature data from STOP and GO, a phase III, randomized, multicentre study. (S. Yalcin; Poster Board 28C, Abstract # 3565)
A Avastin H Herceptin P Pertuzumab
E Erivedge MTP MabThera T Tarceva Gastrointestinal (colorectal cancer)
Session time: 08.00 – 12.00 Venue: S Hall A2 Sequential first-line treatment for metastatic colorectal cancer A with capecitabine, irinotecan, and bevacizumab: Capecitabine X plus bevacizumab (Cape-Bev) versus capecitabine, irinotecan plus bevacizumab (CAPIRI-Bev): The AIO KRK 0110 / ML22011 randomized, phase III trial. (C.A. Giessen; Poster Board 39D, Abstract # TPS3639)
Leukemia, Myelodysplasia, and Transplantation
Session time: 13.15 – 17.15 Venue: S Hall A2 Pharmacokinetics (PK) and pharmacodynamics (PD) of rituximab MT administered by faster infusion in patients with previously untreated diffuse large B-cell (DLBCL) or follicular lymphoma (FL). (M. Brewster; Poster Board 21B, Abstract # 6591)
Tumor Biology
Session time: 11.30 - 12.30 Venue: S100a T Dynamic contrast-enhanced MRI versus 18FMISONIDAZOL- PET/CT to predict pathological response in bevacizumab-based neoadjuvant therapy in breast cancer. (J.G. Foncillas; Poster Board 5, Abstract # 10512)
MM Onartuzumab (MetMAb) X Xeloda
T Trastuzumab emtansine (T–DM1) Z Zelboraf Tuesday June 5
POSTER DISCUSSION SESSION Lung Cancer – Non-small Cell Metastatic
Session time: 08.00 - 12.00 Venue: E450a Presentation time: 11.30 - 12.30 Venue: E354a A randomized placebo-controlled phase III study of intercalated T erlotinib with gemcitabine/platinum in first-line advanced non- small cell lung cancer (NSCLC): FASTACT-II. (T. Mok; Poster Board 9, Abstract # 7519)
Session time: 08.00 - 12.00 Venue: E450a Presentation time: 11.30 - 12.30 Venue: E354a Overall survival (OS) results from OPTIMAL (CTONG0802), T a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC). (C. Zhou; Poster Board 10, Abstract # 7520)
Session time: 08.00 - 12.00 Venue: E450a Presentation time: 11.30 - 12.30 Venue: E354a Phase II Trials of Erlotinib (OSI-774)(E) and Bevacizumab (B) T in Advanced (Adv) Bronchioloalveolar Carcinoma (BAC) and A Adenocarcinoma with BAC Features (adenoBAC), or in Never- Smokers with Primary Adv NSCLC Adenocarcinoma (adenoCa). (H.L. West; Poster Board 7, Abstract # 7517)
A Avastin H Herceptin P Pertuzumab
E Erivedge MTP MabThera T Tarceva Lung Cancer – Non-small Cell Metastatic
Session time: 08.00 - 12.00 Venue: E450a Presentation time: 11.30 - 12.30 Venue: E354a T EGFR compound mutants discriminate survival to erlotinib in non-small-cell lung cancer (NSCLC) patients (p) in the EURTAC study. (R. Rosell; Poster Board 12, Abstract # 7522)
Tumor Biology
Session time: 08.00 - 12.00 Venue: S102 Presentation time: 11.30 - 12.30 Venue: S100a A Dynamic contrast-enhanced MRI versus 18FMISONIDAZOL- PET/CT to predict pathological response in bevacizumab-based neoadjuvant therapy in breast cancer. (J.G. Foncillas; Poster Board 5, Abstract # 10512)
MM Onartuzumab (MetMAb) X Xeloda
T Trastuzumab emtansine (T–DM1) Z Zelboraf Hotels
E SwissÔtel Chicago 323 East Wacker Drive Chicago, IL, 60601–9722 Phone: + 1–312–565–05–65 Breakfast: Restaurant Geneva Mon-Fri: 06.30 – 10.30 Sat-Sun: 06.30 - 12.00
F Double Tree Magnificent Mile 300 E. Ohio Street Chicago, IL, 60611 Phone: + 1-312-787-6100 Breakfast: Private Banquet Room June 1 to 5: 06.30 - 09.00 May 30/31 & June 6: Restaurant Markethouse 06.00 - 11.00
G W Lake Shore 644 N Lake Shore Dr Chicago, IL, 60611, United States Phone: + 1–312–943–92–00 Breakfast: ALTITUDE Ballroom, 33rd Floor 06.30 – 10.30
H Hotel Palomar Chicago 505 North State Street Chicago, IL, 60654 Phone: + 1-312-755-9703 Breakfast: Private Banquet Room June 1: Contemporary Room June 2 to 5: Gallery Ballroom Mon-Sun: 06.00 - 09.30 I SpringHill Suites Chicago Downtown/River North 410 North Dearborn Street Chicago, IL, 60654 Phone: + 1-312-567-1234 Breakfast: Breakfast Room (lobby area) Mon-Fri: 06.30 - 09.00 Sat-Sun: 07.30 - 10.00
J Hyatt Regency McCormick Place 2233 S. Martin L. King Dr. Chicago, IL, 60616 Phone: + 1–312–567–12–34 Breakfast: Restaurant Shore 06.30 - 11.00 Maps
N Lasalle Boulevard
W Division Street
N State Street Chicago metropolitan area Pfc Milton W Chicago Avenue D G Olive Park Milwaukee Avenue McCormickville A F
H N Lake Shore Drive W Ohio Street I B E W Kinzie Street
90
N Lasalle Street
41 Chicago
S Lake Shore Drive Harbour Loop 94
290 Congress Pkwy C
90
S Halsted Street W Roosevelt Road
S Michigan Avenue
S State Street
41 Burnham Park Harbour
th 94 W 18 Street W 18th Street
S Canal Street J K 90 E Cermak Road
Dan
Ryan 55 Stevenson Expy
A Chicago Marriott Downtown G W Chicago Lakeshore Magnificent Mile
B Hyatt Regency H Hotel Palomar Chicago
C Hilton Chicago I Springhill Suites Chicago Downtown/River North
D The James Chicago J Hyatt Regency McCormick Place
E Swissôtel Chicago K McCormick Place Convention Center
F Doubletree Hotel Chicago Magnificent Mile 290 Glenview Mt Prospect
90 Elk Evanston Grove Des Plaines Skokie
Lincolnwood 90 Kennedy Expy O Schiller 41 Park 90 Kennedy Expy 294 ADFG E Elmhurst B Oak Park C Dwight D. Eisenhower Expy 290 K J see Page 32 Tri-State Toll way Chicago Cicero Brookfield 55 90
M 41 Stevenson Expy Dan Ryan Expy
55
Willow Springs Burbank
Palisades Oak Lawn 57
Chicago O’Hare Chicago Midway O International Airport M International Airport Notes
Published by F. Hoffmann-La Roche Ltd Global Oncology Marketing Services CH-4070 Basel, Switzerland
© 2012
All trademarks mentioned herein are protected by law www.roche.com
ASCO 2012 v1.0